Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2
- PMID: 2200748
- DOI: 10.1038/icb.1990.16
Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2
Abstract
Immunization of two macaque monkeys with recombinant vaccinia viruses encoding the env gene of HIV-1 (VV-gp160) resulted in demonstrable levels of gp160, gp120 and gp41-specific immunoglobulins in both animals. The virus used to immunize one of the monkeys additionally expressed the human IL-2 gene, which encoded human IL-2 (VV-gp160-IL-2). No toxic side-effects of vaccine-delivered IL-2 were observed. Despite marked attenuation of virulence by the coexpressed lymphokine, the levels of vector-specific antibodies in both animals were similar. Some differences in the HIV-specific reactivity patterns were detected. Serum reactivity of monkey #A56 (VV-gp160) was directed against gp41, whereas monkey #B58 (VV-gp160-IL-2) showed a wider range of recognition, with higher antibody titres against the HIV lysate preparation. Furthermore, this study demonstrates the capacity to boost antibody responses to the vector and coexpressed HIV antigens in primates which are already immune.
Similar articles
-
Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.AIDS Res Hum Retroviruses. 1994 Feb;10(2):205-12. doi: 10.1089/aid.1994.10.205. AIDS Res Hum Retroviruses. 1994. PMID: 8198873
-
Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2443-7. doi: 10.1073/pnas.90.6.2443. Proc Natl Acad Sci U S A. 1993. PMID: 8460155 Free PMC article. Clinical Trial.
-
Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein.Virology. 1989 Nov;173(1):323-9. doi: 10.1016/0042-6822(89)90250-x. Virology. 1989. PMID: 2510402
-
Current approaches to vaccination against human immunodeficiency viruses.Allergol Immunopathol (Madr). 1991 Jan-Feb;19(1):11-3. Allergol Immunopathol (Madr). 1991. PMID: 1719790 Review. No abstract available.
-
Human trials of AIDS vaccines: current status and future directions.AIDS. 1989;3 Suppl 1:S125-9. AIDS. 1989. PMID: 2558684 Review. No abstract available.
Cited by
-
Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.Vaccine. 2010 Oct 8;28(43):7081-91. doi: 10.1016/j.vaccine.2010.08.008. Epub 2010 Aug 20. Vaccine. 2010. PMID: 20728526 Free PMC article.
-
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.J Immunol. 1995 May 15;154(10):5282-92. J Immunol. 1995. PMID: 7730632 Free PMC article.
-
Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1.Immunology. 1998 Jul;94(3):438-44. doi: 10.1046/j.1365-2567.1998.00533.x. Immunology. 1998. PMID: 9767429 Free PMC article.
-
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8. doi: 10.1073/pnas.93.21.11341. Proc Natl Acad Sci U S A. 1996. PMID: 8876137 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources